Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Shares Gap Up - What's Next?

Swedish Orphan Biovitrum (OTCMKTS:BIOVF - Get Free Report) shares gapped up prior to trading on Thursday . The stock had previously closed at $27.06, but opened at $29.25. Swedish Orphan Biovitrum shares last traded at $29.25, with a volume of 235 shares trading hands.

Swedish Orphan Biovitrum Stock Performance

The company has a market cap of $10.41 billion, a price-to-earnings ratio of 27.59 and a beta of 0.44. The business's 50 day moving average price is $30.11 and its 200-day moving average price is $29.23. The company has a current ratio of 1.04, a quick ratio of 0.71 and a debt-to-equity ratio of 0.31.

Swedish Orphan Biovitrum (OTCMKTS:BIOVF - Get Free Report) last issued its quarterly earnings data on Tuesday, April 29th. The company reported $0.26 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.22 by $0.04. Swedish Orphan Biovitrum had a net margin of 15.07% and a return on equity of 10.54%. The firm had revenue of $641.33 million during the quarter, compared to the consensus estimate of $644.12 million.

Swedish Orphan Biovitrum Company Profile

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection.